<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056467</url>
  </required_header>
  <id_info>
    <org_study_id>2021.249</org_study_id>
    <nct_id>NCT05056467</nct_id>
  </id_info>
  <brief_title>Labor Induction in Preeclampsia High-risk Women</brief_title>
  <acronym>FORECAST-IOL</acronym>
  <official_title>Labor Induction Versus Expectant Management in High-risk Women for Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanoi Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and&#xD;
      mortality. This pregnancy-specific disorder poses to both pregnant women and their offspring&#xD;
      an increased risk of immediate and long-term health problems. The study team is conducting a&#xD;
      study entitled &quot;FORECAST&quot; (Implementation of First-trimester Screening and preventiOn of&#xD;
      pREeClAmpSia Trial) and established the infrastructure for the first-trimester &quot;screen and&#xD;
      prevent&quot; program for preterm PE. However, there is no established evidence regarding the&#xD;
      benefit of scheduled labor induction versus expectant management among women identified as&#xD;
      high-risk for PE with uncomplicated pregnancy at term. The investigators postulate that&#xD;
      induction of labor at 39 weeks' gestation may possibly be an effective intervention to reduce&#xD;
      placental complications in women with uncomplicated pregnancy by 39 weeks at high-risk PE&#xD;
      women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of adverse placental outcomes</measure>
    <time_frame>At Delivery</time_frame>
    <description>To compare the difference in the rate of adverse placental outcomes (PE, gestational hypertension (GH), SGA, stillbirth, perinatal death, placental abruption) in the induction of labor group with the expectant management group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of adverse maternal outcomes</measure>
    <time_frame>6 weeks Postpartum</time_frame>
    <description>To compare the difference in the rate of maternal secondary outcomes including composite outcomes of the following: Cesarean delivery/indication for Cesarean delivery, operative vaginal delivery, indication for operative vaginal delivery, uterine incisional extensions during Cesarean delivery, chorioamnionitis, third-degree or fourth-degree perineal laceration, postpartum hemorrhage, postpartum infection, venous thromboembolism, number of hours in the labor and delivery unit, length of postpartum hospital stay, admission to the intensive care unit, and maternal death, between the induction of labor group and the expectant management group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of adverse neonatal outcomes</measure>
    <time_frame>28 days after birth</time_frame>
    <description>To compare the difference in the rate of neonatal secondary outcomes including the composite outcomes of the following: perinatal death or severe neonatal complications and consisted of one or more of the following during the antepartum or intrapartum period or during the delivery hospitalization between the induction of labor group and the expectant management group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">825</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preeclampsia High-risk Women schedule labor induction at 39 weeks of gestation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expectant Management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Preeclampsia High-risk Women under expectant management</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Induction of Labor</intervention_name>
    <description>Induction of Labor at 39 weeks of gestation</description>
    <arm_group_label>IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age no less than 18 years&#xD;
&#xD;
          -  Singleton pregnancy with cephalic presentation and no contraindication to vaginal&#xD;
             delivery&#xD;
&#xD;
          -  Live fetus&#xD;
&#xD;
          -  Screened high-risk for PE&#xD;
&#xD;
          -  Informed and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Pregnant women who plan to have Cesarean delivery&#xD;
&#xD;
          -  Pregnancies complicated by the major fetal abnormality&#xD;
&#xD;
          -  Women who are severely ill, those with learning difficulties, or serious mental&#xD;
             illness&#xD;
&#xD;
          -  Pregnant women with medical, obstetric, or fetal complications or any other&#xD;
             indications for delivery before 39 weeks' gestation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liona POON, MD</last_name>
    <phone>35051290</phone>
    <email>liona.poon@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanoi Obstetrics &amp; Gynecology Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chiu Yee Liona Poon</investigator_full_name>
    <investigator_title>Professor (Clinical)</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>biomarker</keyword>
  <keyword>blood pressure</keyword>
  <keyword>hypertension</keyword>
  <keyword>mean arterial pressure</keyword>
  <keyword>placental growth factor</keyword>
  <keyword>pre-eclampsia</keyword>
  <keyword>prediction</keyword>
  <keyword>uterine artery pulsatility index</keyword>
  <keyword>induction of labor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

